Figure 4From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'Baseline CXCL13 stratified by clinical disease activity score (+/-DAS28-remission) after 2 years of therapy. Both treatment groups are considered together. Bars represent median with IQR. *Indicates statistically significant difference (P = 0.03). CXCR13: C-X-C chemokine receptor type 13; DAS28: disease activity score in 28 joints; IQR: interquartile range.Back to article page